38,432 Shares in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Acquired by B. Metzler seel. Sohn & Co. AG

Key Points

• B. Metzler seel. Sohn & Co. AG initiated a stake in Centessa by buying 38,432 shares (about $961,000) in Q4, and institutional investors now own roughly 82.01% of the stock.
• Analysts lean toward a Hold consensus (4 Buy, 9 Hold, 1 Sell) with an average target of $40.70, and several firms recently downgraded the shares.
• Insiders have been net sellers—349,073 shares (~$9.43 million) sold in the last 90 days—and the company recently missed quarterly estimates, reporting a loss of $0.48 per share versus an expected $0.38 loss.

B. Metzler seel. Sohn & Co. AG purchased a new position in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 38,432 shares of the company's stock, valued at approximately $961,000.

A number of other large investors also recently added to or reduced their stakes in CNTA. TD Waterhouse Canada Inc. purchased a new position in Centessa Pharmaceuticals in the 4th quarter worth approximately $25,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Centessa Pharmaceuticals by 26.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,688 shares of the company's stock worth $117,000 after purchasing an additional 979 shares in the last quarter. DNB Asset Management AS purchased a new position in Centessa Pharmaceuticals in the 3rd quarter worth approximately $218,000. GSA Capital Partners LLP purchased a new position in Centessa Pharmaceuticals in the 3rd quarter worth approximately $455,000. Finally, BNP Paribas Financial Markets lifted its holdings in Centessa Pharmaceuticals by 3,028.1% in the 2nd quarter. BNP Paribas Financial Markets now owns 34,972 shares of the company's stock worth $460,000 after purchasing an additional 33,854 shares in the last quarter. 82.01% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms recently commented on CNTA. Stephens cut Centessa Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, March 31st. Leerink Partners downgraded Centessa Pharmaceuticals from an "outperform" rating to a "hold" rating and lifted their price objective for the stock from $36.00 to $40.00 in a research note on Wednesday, April 1st. B. Riley Financial downgraded Centessa Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, March 31st. Chardan Capital reaffirmed a "buy" rating and issued a $30.00 price objective on shares of Centessa Pharmaceuticals in a research note on Friday, January 2nd. Finally, Lifesci Capital downgraded Centessa Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 1st. Four analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Centessa Pharmaceuticals has an average rating of "Hold" and an average target price of $40.70.

Centessa Pharmaceuticals Stock Performance

NASDAQ:CNTA opened at $39.47 on Monday. The company has a debt-to-equity ratio of 0.21, a current ratio of 8.57 and a quick ratio of 8.57. Centessa Pharmaceuticals PLC Sponsored ADR has a 1 year low of $10.95 and a 1 year high of $40.26. The stock's 50 day simple moving average is $31.71 and its two-hundred day simple moving average is $27.35. The company has a market cap of $5.89 billion, a price-to-earnings ratio of -26.85 and a beta of 1.25.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its quarterly earnings data on Tuesday, March 31st. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.10). As a group, equities analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Iqbal J. Hussain sold 38,951 shares of the business's stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $25.15, for a total transaction of $979,617.65. Following the transaction, the insider owned 57,645 shares of the company's stock, valued at approximately $1,449,771.75. The trade was a 40.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Gregory M. Weinhoff sold 73,196 shares of the business's stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $26.33, for a total value of $1,927,250.68. Following the transaction, the insider directly owned 65,925 shares in the company, valued at approximately $1,735,805.25. This represents a 52.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 349,073 shares of company stock valued at $9,429,412. 7.09% of the stock is currently owned by insiders.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.

Want to see what other hedge funds are holding CNTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.